Every Form 4 that USANA Health Sciences Inc (USNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow USNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USNA filings page.
USANA Health Sciences chief information officer Peter Benedict reported equity compensation activity on July 25, 2026. A derivative transaction converted 598 restricted stock units into 598 shares of common stock, and a related Form F transaction withheld 176 common shares at $21.32 per share as payment of exercise price or tax liability. Following the derivative transaction, 38,004 restricted stock units remain outstanding, and each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong reported the vesting and settlement of 1,166 Restricted Stock Units into the same number of common shares on July 25, 2026. In a related transaction, 518 common shares were withheld, reported as payment of exercise price or tax liability at $21.32 per share. Following the RSU conversion, Armstrong directly held 39,426 Restricted Stock Units.
On July 23, 2026, USANA Health Sciences director Timothy E. Wood exercised 1,632 Restricted Stock Units, receiving the same number of common shares. In a related step, 408 shares were withheld to pay the exercise price or tax liability at $20.92 per share. After this conversion, he holds 4,895 Restricted Stock Units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Frederic J. Winssinger, a director of USANA Health Sciences, exercised restricted stock units covering 1,632 shares of common stock on July 23, 2026. The conversion transferred RSUs into shares with no reported market sale, resulting in 9,733 common shares held directly and 4,895 restricted stock units remaining outstanding.
USANA Health Sciences Inc. director J. Scott Nixon reported an equity compensation event on July 23, 2026. He exercised 1,632 Restricted Stock Units, receiving 1,632 shares of common stock. Following this conversion, he directly holds 11,445 common shares and 4,895 Restricted Stock Units.
USANA Health Sciences director Gilbert A. Fuller reported the vesting and conversion of 1,632 Restricted Stock Units into 1,632 shares of common stock on July 23, 2026. After this equity award conversion, he holds 1,632 common shares and 4,895 Restricted Stock Units. Each unit represents a contingent right to one share and vests 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Peggie Pelosi, a director of USANA Health Sciences, exercised 1,632 restricted stock units into an equal number of common shares on July 23, 2026. 935 shares of common stock were withheld at $20.92 per share to cover tax obligations. Following these transactions she directly holds 4,895 restricted stock units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
USANA Health Sciences director John Turman Fleming reported the conversion of 1,632 Restricted Stock Units into 1,632 shares of common stock on July 23, 2026. After this derivative exercise, he directly holds 5,862 common shares and 4,895 Restricted Stock Units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
USANA Health Sciences director Xia Ding reported equity compensation activity on July 23, 2026. Ding exercised 1,632 restricted stock units, receiving the same number of common shares. Also on that date, 604 shares at $20.92 per share were withheld to satisfy the exercise price or tax liability, and 4,895 restricted stock units are reported as directly held afterward.
USANA Health Sciences Chief Commercial Officer Brent Neidig reported an open-market sale of 5,002 shares of Common Stock. The shares were sold at a weighted average price of $19.453 per share, with individual trade prices ranging from $19.35 to $19.68.
Following this transaction, Neidig reported direct ownership of 0 shares of USANA Common Stock.
USANA Health Sciences chief commercial officer Brent Neidig reported two open-market sales of common stock. On June 12, he sold 1,602 shares at $20.15 per share. On June 15, he sold an additional 909 shares at $20.005 per share. After these transactions, he directly holds 5,002 shares of USANA common stock.
USANA Health Sciences chief people officer Paul A. Jones sold 5,561 shares of company common stock in an open-market transaction at $18.50 per share. Following this sale, he reported holding no shares of USANA common stock directly.
USANA Health Sciences director John Turman Fleming sold shares in the company. He completed an open-market sale of 2,450 shares of USANA common stock at a price of $17.93 per share. After this transaction, he directly holds 4,230 shares, indicating he retains a meaningful personal stake in the company despite the sale.
USANA Health Sciences executive Paul A. Jones, the company’s Chief People Officer, sold 6,813 shares of Common Stock in an open-market transaction at a price of $18.95 per share.
After this sale, Jones directly holds 5,561 shares of USANA stock, and no derivative positions are shown in this filing.
USANA Health Sciences' Chief Financial Officer, Doug G. IIEKKING, reported selling 5,360 shares of the company’s Common Stock in an open-market transaction. The sale occurred at an average price of $18.7525 per share. Following this transaction, his directly held Common Stock position reported in this filing is zero shares.
USANA Health Sciences director Gilbert A. Fuller reported an open-market sale of 1,057 shares of USANA common stock. The trade on May 22, 2026 was executed at a weighted average price of $18.6648 per share, within a price range of $18.62 to $18.775. Following this transaction, the filing shows Fuller holding 0 directly owned shares of USANA common stock.
WOOD TIMOTHY E reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Timothy E. Wood received an equity grant of 6,527 restricted stock units. Each unit represents a right to receive one share of USANA common stock if it vests. The award vests in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. After this grant, Wood holds 6,527 restricted stock units directly.
Nixon J Scott reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director J Scott Nixon received a grant of 6,527 restricted stock units. Each unit represents a contingent right to receive one share of USANA common stock. The restricted stock units vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. Following this award, Nixon holds 6,527 restricted stock units directly, reflecting a routine equity-based compensation grant rather than an open-market purchase or sale.
Pelosi Peggie reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Peggie Pelosi received a grant of restricted stock units. She was awarded 6,527 restricted stock units, each representing a right to receive one share of USANA common stock. The units vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Fleming John Turman reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director John Turman Fleming reported receiving a grant of 6,527 restricted stock units, each representing a contingent right to one share of USANA common stock. All 6,527 units were newly awarded and held directly after the transaction.
The restricted stock units vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027, tying the director’s compensation to the company’s longer-term performance and service over this period.
USANA Health Sciences director Frederic J. Winssinger received a grant of 6,527 Restricted Stock Units (RSUs) on May 7, 2026. Each RSU represents a contingent right to receive one share of USANA common stock, so this award could convert into 6,527 shares if fully vested.
The RSUs vest in four equal installments of 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027, encouraging ongoing board service over this period. After this grant, Winssinger holds 6,527 RSUs directly, with no remaining derivative positions reported in this filing.
FULLER GILBERT A reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Gilbert A. Fuller received a grant of 6,527 restricted stock units on May 7, 2026. Each unit represents the right to receive one share of USANA common stock. The award vests in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027, and reflects equity-based compensation rather than an open-market share purchase.
Ding Xia reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Xia Ding received a grant of restricted stock units. The award covers 6,527 RSUs, each representing a contingent right to receive one share of USANA common stock if vesting conditions are met.
The RSUs vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. Following this grant, Ding holds 6,527 restricted stock units directly, reflecting a routine equity-based compensation award rather than an open-market stock purchase or sale.
USANA Health Sciences Inc chief legal officer Joshua Foukas reported an open-market sale of company stock. On May 7, 2026, he sold 3,791 shares of Common Stock at $19.82 per share. After this transaction, his directly owned Common Stock holdings reported in this filing were reduced to 0 shares.
USANA Health Sciences director Timothy E. Wood reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into 1,057 shares of common stock, reflecting a derivative exercise with no cash purchase.
On the same date, 264 common shares were disposed of at $19.24 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market. Following these transactions, Wood directly held 10,613 shares of USANA common stock.
USANA Health Sciences director Frederic J Winssinger exercised restricted stock units into common stock, acquiring 1,057 shares. Following this transaction, he directly holds 8,101 shares of USANA common stock. Each restricted stock unit represents a contingent right to receive one share, with vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director J. Scott Nixon reported exercising 1,057 restricted stock units into an equal number of USANA common shares on April 23, 2026. Following this transaction, he directly holds 9,813 shares of common stock. Each restricted stock unit represented a right to receive one USANA share, and the units vested in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Gilbert A. Fuller exercised 1,057 restricted stock units into common stock. On April 23, 2026, 1,057 RSUs converted into 1,057 shares of USANA common stock at a stated price of $0.00 per share. After the transaction, he directly holds 1,057 common shares and no remaining RSUs under this grant.
Each restricted stock unit represented a contingent right to receive one share of common stock, with the grant vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Peggie Pelosi reported routine equity compensation activity involving restricted stock units and common shares. On April 23, 2026, 1,057 restricted stock units were exercised into 1,057 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 668 common shares were disposed of at $19.24 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Pelosi directly held 5,364 shares of USANA common stock.
USANA Health Sciences director John Turman Fleming exercised 1,057 Restricted Stock Units into Common Stock on April 23, 2026. The RSUs converted into 1,057 shares of USANA common stock, increasing his directly held position to 6,680 shares after the transaction. Each RSU represented a contingent right to receive one share of common stock, with this grant vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Xia Ding reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into common stock, reflecting a derivative exercise tied to prior awards. To cover tax obligations, 391 shares of common stock were withheld and disposed of at $19.24 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Xia Ding directly held 7,250 shares of USANA common stock.
USANA Health Sciences director Gilbert A. Fuller sold shares in an open-market transaction. He sold 1,058 shares of common stock at a price of $17.00 per share. After this sale, the filing shows he directly owns 0 shares of USANA common stock.
USANA Health Sciences' chief information officer, Peter Benedict, sold 4,553 shares of company common stock in an open-market transaction. The shares were sold at a weighted average price of $19.3848 per share, with individual trade prices ranging from $19.29 to $19.415. Following this sale, Benedict reported owning no shares of USANA common stock directly.
USANA Health Sciences' Chief Operating Officer Walter Noot reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised or converted 7,422 restricted stock units, each representing a right to receive one share of USANA common stock.
This conversion resulted in the acquisition of 7,422 shares of common stock at no exercise price, and a remaining balance of 75,130 restricted stock units held directly after the transaction. Following the stock acquisition, 3,144 common shares were disposed of at $21.52 per share to satisfy tax obligations by delivering shares.
After these transactions, Noot directly owned 9,256 shares of USANA common stock. Footnotes state that the restricted stock units vest 25% on the anniversary of February 27, 2025, linking these movements to the vesting schedule of prior equity awards.
USANA Health Sciences chief commercial officer Brent Neidig reported equity award activity involving restricted stock units and common shares. He exercised 6,747 restricted stock units, each representing a right to receive one USANA common share, and acquired 6,747 common shares at no cash price. On the same date, 2,993 common shares were withheld at $21.52 per share to satisfy tax obligations related to the award, leaving him with 7,513 directly owned common shares and 67,447 restricted stock units. The restricted stock units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences Chief People Officer Paul A. Jones reported equity compensation activity involving restricted stock units and common shares. On February 27, 4,596 restricted stock units were exercised and converted into 4,596 shares of common stock at a price of $0.00 per share. A separate transaction on the same date disposed of 1,349 common shares at $21.52 per share to cover tax obligations through share withholding. After these transactions, Jones directly held 46,611 restricted stock units and 12,374 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences' chief financial officer IIEKKING G DOUG reported equity award activity. On February 27, 2026, he exercised 7,469 Restricted Stock Units, converting them into the same number of common shares at $0.00 per share. Following this conversion, his directly held common stock position was 10,391 shares before a separate tax transaction. On the same date, 5,031 common shares were disposed of at $21.52 per share to cover tax obligations, leaving him with 5,360 common shares held directly. Footnotes state each restricted stock unit represents one share of common stock and that these units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief legal officer Joshua Foukas reported equity compensation activity tied to restricted stock units. On February 27, 2026, 6,577 restricted stock units were exercised into 6,577 shares of common stock at $0.00 per share, reflecting a vesting event rather than an open‑market purchase. On the same date, 2,786 shares of common stock were disposed of at $21.52 per share to satisfy tax obligations through share withholding, not a market sale. Following these transactions, Foukas directly held 3,791 shares of common stock and 66,693 restricted stock units, each representing a contingent right to receive one share of USANA common stock.
USANA Health Sciences CEO and executive chairman Kevin Guest reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised 7,856 restricted stock units, converting them into 7,856 shares of common stock at a stated price of $0.0000 per share. A separate entry shows 3,328 shares of common stock disposed of at $21.52 per share to satisfy tax obligations through share delivery, a non‑market, tax‑withholding transaction. Following these transactions, he directly held 45,381 shares of common stock and 127,206 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of USANA common stock, and the units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief information officer Peter Benedict reported equity award activity involving restricted stock units and common shares. On February 27, 2026, he exercised 3,906 restricted stock units, each convertible into one share of USANA common stock, and received 3,906 common shares at a stated price of $0.0000 per share. To cover tax obligations from this vesting, 1,174 common shares were disposed of through a tax-withholding transaction at $21.52 per share. After these transactions, Benedict directly held 38,602 restricted stock units and 4,553 common shares of USANA. The restricted stock units represent a contingent right to receive one share of common stock each and vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong reported equity award activity involving restricted stock units and common stock. She exercised or converted 4,190 restricted stock units into the same number of common shares at a stated price of $0.00 per share.
On the same date, 2,015 common shares were disposed of at $21.52 per share to satisfy tax obligations through share withholding, rather than an open‑market sale. After these transactions, she directly owned 2,823 shares of USANA common stock, and 40,592 restricted stock units remained following the derivative transaction.
USANA Health Sciences chief legal officer Joshua Foukas reported two transactions involving company equity. On February 19, 2026, he acquired 36,662 restricted stock units, each representing a right to receive one share of USANA common stock, bringing his RSU holdings to 73,270 units. On February 20, 2026, he executed an open-market sale of 4,461 shares of common stock at an average price of $21.345 per share, after which his directly held common stock position was reported as 0 shares.
Benedict Peter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Information Officer, Peter Benedict, received a grant of 21,775 Restricted Stock Units (RSUs) on February 19, 2026. Each RSU represents a contingent right to receive one share of USANA common stock.
The grant vests in four equal installments of 25% on each February 19 after the grant date, aligning the executive’s compensation with the company’s long-term performance. Following this award, Benedict directly holds 42,508 RSUs in total.
Armstrong Kathryn Michelle reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong received a grant of 24,526 restricted stock units on February 19, 2026. Each unit represents a contingent right to receive one share of USANA common stock. After this grant, she beneficially owns 44,782 restricted stock units directly. The units vest in four equal 25% installments on each February 19 following the grant date.
Noot Walter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief operating officer Walter Noot received a grant of 41,373 restricted stock units on February 19, 2026. Each unit represents the right to receive one share of USANA common stock and vests 25% on each following February 19. After this award, he directly holds 82,552 restricted stock units.
USANA Health Sciences reported that Chief Commercial Officer Brent Neidig acquired 37,610 restricted stock units on February 19, 2026 as a grant. Each unit represents a contingent right to receive one share of USANA common stock. Following this award, Neidig directly holds 74,194 restricted stock units. The grant is scheduled to vest 25% on each February 19 after the grant date.
USANA Health Sciences reported that Chief People Officer Paul A. Jones acquired 25,622 restricted stock units on February 19, 2026 as a grant or award. Each restricted stock unit represents a contingent right to receive one share of USANA common stock. The grant vests in four equal installments of 25% on each February 19 after the grant date. Following this award, Jones holds 51,207 restricted stock units directly.
IIEKKING G DOUG reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Financial Officer, Doug G. Iieekking, received a grant of 41,639 restricted stock units on February 19, 2026. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
The award vests in stages, with 25% of the units vesting on each 19th of February thereafter. Following this grant, the officer directly holds 83,218 restricted stock units, aligning a portion of his compensation with the company’s future share performance.
USANA Health Sciences CEO Kevin Guest reported an equity award. On February 19, 2026, he acquired 82,726 restricted stock units at a stated price of $0.00 per unit. Each unit is a contingent right to receive one share of USANA common stock.
The restricted stock units vest 25% on each 19th of February thereafter under the grant terms. Following this award, Guest directly held a total of 135,062 restricted stock units in USANA.
USANA Health Sciences chief information officer Benedict Peter reported multiple equity transactions in early February 2026. On three dates, restricted stock units converted into common shares at an exercise price of $0, increasing his directly held common stock and reducing his RSU balance.
Across these transactions, some common shares were disposed of at $21.34 per share under transaction code F, leaving Peter with 1,821 shares of USANA common stock and 20,733 restricted stock units held directly after the reported activity.